Four companies have signed a share subscription agreement to transform Alfenax Biologics into a joint venture to establish domestic manufacturing capacity for biosimilars. The investment ratios remain as currently disclosed, with payment expected to be completed by 2026-11-25. Commercial production is targeted for the fiscal year ending March 2031.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4584","jir_company_name":"Kidswell Bio Corporation","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-09","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/4584-20261109-01.pdf","jir_short_summary":"Four companies have signed a share subscription agreement to transform Alfenax Biologics into a joint venture to establish domestic manufacturing capacity for biosimilars. The investment ratios remain as currently disclosed, with payment expected to be completed by 2026-11-25. Commercial production is targeted for the fiscal year ending March 2031.","jir_summary":"### Overview and Background\nThis matter announces that four companies, centered on Alfenax Biologics, have agreed to a share subscription agreement to establish a joint venture to build domestic manufacturing capacity in the biosimilar market. The parties will collaboratively construct and operate domestic manufacturing facilities and establish a domestically integrated CDMO structure for biopharmaceuticals and related products.\n\n### Future Schedule and Impact\nThe dates for signing the share subscription agreement and its execution have been disclosed; the joint venture structure will be established after payment completion. The impact on consolidated results from fiscal 2027 onward is expected to be minor, and a phased plan targeting the start of commercial production in the fiscal year ending March 2031 has been presented.","jir_financial_highlights":"Investment ratio (provisional): 45%, 45%, 7%, 3% (Planned to be the same as the current disclosed ratios)\nCapital (Alfenax Biologics): 1,201 million yen (After payment completion)\nTarget for start of commercial production: Targeting by the fiscal year ending March 2031 (Planned)","jir_category":"","jir_hashtags":"#KidswellBio, #JointVentureFormation, #BiosimilarManufacturing, #DomesticManufacturingInfrastructure","jir_key_figures":"Share subscription agreement signing date: 2026-11-09\nPlanned share subscription execution date: 2026-11-25\nInvestment ratios: 45% \/ 45% \/ 7% \/ 3%","jir_meta_title":"Kidswell Bio Corporation: Share Subscription Agreement for Joint Venture Formation\uff5cAdvancing Domestic Manufacturing Infrastructure","jir_meta_description":"Four companies including Alfenax Biologics signed a share subscription agreement to form a joint venture. Investment ratios are 45\/45\/7\/3; joint venture will be established after payment completion. Commercial production targeted by the fiscal year ending March 2031.","jir_og_title":"Share Subscription Agreement to Form Joint Venture, Promoting Domestic Manufacturing Infrastructure | Kidswell Bio Corporation","jir_og_description":"Four companies will jointly invest to establish Alfenax Biologics as a joint venture, aiming to strengthen domestic biosimilar manufacturing capacity and ensure stable supply. Commercial production is targeted for the fiscal year ending March 2031.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":58797,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"m_and_a_alliance","footnotes":""},"sector":[],"importance":[],"class_list":["post-145827","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n